Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.

In this study, researchers optimized the soft drug AR antagonist 14-P1 to create candidate 39, which demonstrated effective AR antagonism and safety in a hair-growth mouse model, showing similar efficacy to pyrilutamide but with quicker onset and a lower risk of systemic toxicity.

In a hair-growth mouse model, this study reported that the novel AR antagonist candidate 39, derived from structural optimization of 14-P1, achieved similar efficacy to pyrilutamide with faster response and maintained safety, demonstrating potent AR antagonism and favorable pharmacokinetics with lower systemic toxicity risk.

This study found that the optimized AR antagonist compound 39 showed potent hair growth activity with improved safety in mice, suggesting potential for better topical treatments for androgenetic alopecia.

In a mouse hair-growth model, this study found that the optimized compound 39 matched the efficacy of pyrilutamide for androgenic alopecia, with faster response and maintained safety, suggesting it as a promising topical AR antagonist with reduced systemic toxicity risk.

In this study, a dual soft drug design strategy improved the AR antagonist candidate 39, showing potent AR antagonism and good safety in a mouse hair-growth model, with similar efficacy to pyrilutamide but faster response.

This study found that the optimized AR antagonist candidate 39, in a hair-growth mouse model, achieved similar efficacy to pyrilutamide with faster onset and favorable safety, suggesting a promising approach for developing topical treatments with low systemic toxicity for androgenetic alopecia.

This study reports that the newly optimized AR antagonist 39 demonstrated effective hair growth and safety in a mouse model of androgenetic alopecia, showing comparable efficacy to pyrilutamide with faster response and favorable pharmacokinetics, due to innovative structural design and dual metabolic inactivation strategy.

In this case report, a 9-year-old boy with Sjogren-Larsson syndrome was also diagnosed with central precocious puberty, showing genetic mutations and increased hormone levels; he was treated with triptorelin acetate for CPP but experienced growth delay during follow-up.

In this case report, researchers observed a Slovakian neonate with a rare EGFR genetic mutation who presented with severe neonatal dermatoses, ichthyosis, and multisystem complications, emphasizing the significance of genetic diagnosis for such complex conditions.

This article notes the lack of US prevalence data for primary lymphocytic cicatricial alopecias due to the recent introduction of subtype-specific ICD-10 codes and highlights the importance of early diagnosis for hair preservation.

This review found that adding immune checkpoint inhibitors to cancer treatment regimens likely increases the incidence of specific drug-related skin toxicities in adult Asian patients, highlighting the need for careful monitoring and management strategies.

This study identified a specific hemizygous intronic variant in the MBTPS2 gene associated with IFAP syndrome in a patient, revealing exon skipping and reduced normal transcript expression through long-read RNA sequencing.

This study developed and validated a simple, cost-effective UV–Visible spectrophotometric method for estimating finasteride in pharmaceuticals, demonstrating good linearity, accuracy, precision, and sensitivity according to ICH guidelines, making it suitable for routine quality control.

In this article, the authors describe a successfully treated case of a newborn with ichthyosis using a neonatal protocol involving an incubator with controlled temperature and humidity, sepsis prevention, eye protection, and emollient care without keratolytics during the early neonatal period.

This study found that ritlecitinib 50 mg is cost-effective compared to no treatment for patients in Japan with alopecia areata and significant scalp hair loss, demonstrating an incremental cost-effectiveness ratio below the country's cost-effectiveness threshold.

In this study, among 450 patients treated with immune checkpoint inhibitors for metastatic melanoma, 1.33% developed scarring alopecia, all being female, with alopecia not impacting their cancer treatment continuation and a favorable cancer outcome reported.

In this case series, researchers reported scarring alopecia in six out of 450 patients (1.33%) treated with immune checkpoint inhibitors for metastatic melanoma, with all affected patients experiencing other immune-related adverse effects but continuing treatment with favorable cancer outcomes.

In this study, researchers reported a 1.33% prevalence of scarring alopecia among 450 patients treated with immune checkpoint inhibitors for metastatic melanoma, noting that hair loss did not require treatment discontinuation and seemed to coincide with favorable cancer outcomes.

This study found that GPT-4o demonstrated high concordance with in-person and image-based provider assessments in generating SALT scores for alopecia areata, suggesting its potential as an adjunct tool in clinical practice for automating these assessments.

This review discusses identifying keratosis pilaris, its common mimics, and its associated skin diseases across different skin tones but reports no new results.

This study found that a nomogram prediction model based on clinical characteristics, bone metabolism, and ovarian function can effectively predict the treatment response to long-acting GnRHa in girls with idiopathic central precocious puberty.

This study explored the intersection of art and medicine, specifically examining the depiction of the malar rash associated with lupus in historical paintings. The authors suggest that this approach, known as iconodiagnosis, can enhance medical education and understanding of disease manifestations through visual arts.

In this study, researchers reported that dermoscopic examination of eyebrow hairs can help in the early diagnosis of Netherton syndrome in children by detecting trichorrhexis invaginata, facilitating prompt counseling and care while awaiting genetic test results.

In this laboratory study, the researchers reported that an ethnomedicinal hair growth formula from East Nusa Tenggara, incorporating Kemiri, Kembang sepatu, Beringin, Mangkokan, and Waru, demonstrated significant antioxidant activity and effectively stimulated hair growth, suggesting potential development as a natural cosmeceutical.

This study found that the highest antioxidant-activity formulation of the RENTT herbal combination effectively stimulated hair growth in mice and may serve as a natural therapy for chemotherapy-induced alopecia.

This study found that Justicia procumbens aqueous extract promoted hair regrowth and alleviated aging-related hair and vascular deterioration in mice, indicating potential benefits for maintaining hair health as aging progresses, though further research is needed for human validation.

Radiation-induced hair loss may be caused by hair growth stopping and inflammation in blood vessels.

This study provides a detailed cellular atlas of cutaneous squamous cell carcinoma, indicating that different fibroblast subtypes play roles in tumor progression and suppression, with potential biomarkers identified for HPV-related tumor growth.

In this case report, a 6-year-old boy with Netherton syndrome was diagnosed using trichoscopy, which revealed characteristic hair shaft abnormalities such as bamboo, golf tee, and matchstick hairs.